Trials of gene therapy for spinomuscular atrophy and stem cell treatments for ALS look promising.
A small set of biomarkers in CSF and plasma may predict progression to Alzheimer’s within three years.
Lawmakers have earmarked an additional $350 million for Alzheimer’s research, the largest increase in history.
Researchers detect liaisons between amyloid precursor protein and β-secretase in Golgi-derived vesicles and recycling endosomes, providing clues to where Aβ could form.
Computerized assessments and electroencephalography both hold promise for diagnosis and drug testing in Alzheimer’s disease, but the Food and Drug Administration does not yet know how to oversee the technology.
A new registry will match healthy volunteers with Alzheimer’s clinical trials based on ApoE genotype.
NIH announced a five-year study of Alzheimer’s biomarkers in middle-aged people with Down’s syndrome.
Scientists find that aggregates of different types of protein hinder the flow of nucleocytoplasmic transport, suggesting a common mechanism for neurodegeneration.
The BRCA1 protein protects neurons from DNA damage, but levels tumble in Alzheimer’s disease.
Mouse lines made by two different labs replicate the molecular pathology, but not the neurodegeneration, of ALS and FTD based on C9ORF72 expansions.
In various animal models of traumatic brain injury, acute treatments quiet inflammation and preserve neurons and their myelin sheaths.
Altered responses to visual stimuli could signify the extent of TDP-43 pathology in the brain, researchers predict.
Researchers at this year’s SfN meeting detailed different strategies and outcomes of passive and active vaccines.
The leaders of two large European trials report that promoting cardiac health, exercise, and mental activity helped maintained cognition in older adults.
Forget transgenics for a moment. Large collections of inbred and outbred mice could be an untapped treasure trove for Alzheimer’s researchers.
No filters selected